T1	intervention 94 114	docetaxel-epirubicin
T2	control 119 161	5-fluorouracil-epirubicin-cyclophosphamide
T3	location 235 241	Mexico
T4	eligibility 535 601	patients with locally advanced breast cancer (stages IIB and IIIA)
T5	total-participants 864 873	Forty one
T6	control-participants 960 962	21
T7	intervention-participants 988 990	20
T8	outcome 1011 1044	Dimensional pathological response
T9	outcome 1193 1223	complete pathological response
T10	cv-bin-abs 1110 1114	Five
T11	iv-bin-abs 1149 1152	ten
T12	outcome 1273 1283	leucopenia
T13	outcome 1285 1296	neutropenia
T14	outcome 1301 1306	fever
T15	outcome 1368 1384	general survival
T16	outcome 1342 1363	disease-free survival
T17	outcome 1319 1340	number of lymph nodes
T18	outcome 1308 1317	Morbidity
T19	outcome 1441 1450	mortality
T20	outcome 1577 1607	complete pathological response
T21	outcome 1660 1681	pathological response
T22	control 628 686	5-fluorouracil-epirubicin-cyclophosphamide (control group)
